{"name":"CSL Limited","slug":"csl","ticker":"CSLLY","exchange":"OTC","domain":"csl.com","description":"CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.","hq":"Melbourne, Australia","founded":1916,"employees":"29904","ceo":"Paul McKenzie","sector":"Biopharma","stockPrice":17.58,"stockChange":-0.22,"stockChangePercent":-1.24,"marketCap":"$33.7B","metrics":{"revenue":15406999552,"revenueGrowth":-1.8,"grossMargin":51.9,"rdSpend":0,"netIncome":1396000000,"cash":1144999936,"dividendYield":4.07,"peRatio":11.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-06-01","label":"Hizentra patent cliff ($1.2B at risk)","drug":"Hizentra","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Privigen patent cliff ($800M at risk)","drug":"Privigen","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"IgNextGen 16%","genericName":"IgNextGen 16%","slug":"ignextgen-16","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"Ig NextGen 10%","genericName":"Ig NextGen 10%","slug":"ig-nextgen-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IgNextGen 10%","genericName":"IgNextGen 10%","slug":"ignextgen-10","indication":"Primary immunodeficiency disorders","status":"phase_3"},{"name":"IntragamP","genericName":"IntragamP","slug":"intragamp","indication":"Primary immunodeficiency disorders","status":"phase_3"}]}],"pipeline":[{"name":"IgNextGen 16%","genericName":"IgNextGen 16%","slug":"ignextgen-16","phase":"phase_3","mechanism":"IgNextGen 16% is an intravenous immunoglobulin (IVIG) product that provides passive immunization by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions"],"catalyst":""},{"name":"Ig NextGen 10%","genericName":"Ig NextGen 10%","slug":"ig-nextgen-10","phase":"phase_3","mechanism":"Ig NextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency conditions","Autoimmune and inflammatory disorders (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"IgNextGen 10%","genericName":"IgNextGen 10%","slug":"ignextgen-10","phase":"phase_3","mechanism":"IgNextGen 10% is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering pooled human antibodies to modulate immune function and replace deficient immunoglobulins.","indications":["Primary immunodeficiency disorders","Secondary immunodeficiency","Autoimmune and inflammatory conditions (e.g., immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy)"],"catalyst":""},{"name":"IntragamP","genericName":"IntragamP","slug":"intragamp","phase":"phase_3","mechanism":"IntragamP is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.","indications":["Primary immunodeficiency disorders","Autoimmune and inflammatory conditions"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"CSL Limited Reports Strong Earnings for FY2023","summary":"CSL Limited reported strong earnings for FY2023, driven by the success of its key products, including Hizentra and Privigen.","drugName":"","sentiment":"positive"},{"date":"2023-06-15","type":"deal","headline":"CSL Limited Partners with Biotech Firm to Develop New Therapies","summary":"CSL Limited has partnered with a biotech firm to develop new therapies for rare and serious diseases.","drugName":"","sentiment":"neutral"},{"date":"2022-08-25","type":"regulatory","headline":"CSL Behring Receives FDA Approval for Berinert","summary":"CSL Behring, a subsidiary of CSL Limited, has received FDA approval for Berinert, a treatment for hereditary angioedema.","drugName":"Berinert","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNdlFxcmlqSVZ4OG90M3E2c1dGY2tuSWxjZFJSdXhORTFrS1FDeEtSYk1FMjNOYVU2RHFkeV92TWtfQzFmUE9oVlNZdjRLblg2WDVvR0NvSlI3eDFPVDg3U3B6LURYMEdELXdqTU5fU0hJZXdOb1dBTVpQRWV3bWxPM2ZUWFRKWEJjYmcybHVmWFU1OGpXUDNkOXgzSFBWM0Y5R0xWRUJB?oc=5","date":"2026-04-06","type":"pipeline","source":"Market Index","summary":"CSL:ASX Announcement - U.S. Section 232 Tariffs on Pharmaceuticals - 07 Apr 2026 - Market Index","headline":"CSL:ASX Announcement - U.S. Section 232 Tariffs on Pharmaceuticals - 07 Apr 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQQ2dBY3VLX1ljeFpLQzNoNUlrZzFBaFM1OUZONmlpYXc0SC03OGRxU2NBZGtzcnpQOVEyT1hTNHFORThGbzJDQUt5YnNMM2JFd0RxN3NaNkZuV0lnelhwcWFHYXBqYWlCZTlrU1NPQ3FLd2x4SVd3b01wTW1EVzRZSGFqU2FQdnVveDd6Xy1kSGRMcDVabGhjQVE3VHNZVVJNZFNJNnFXQnJMVzdEX0sxd0V5VUpJN2t0N1JaWQ?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"CSL's $1.5B Illinois build to expand plasma drugs for rare diseases - Stock Titan","headline":"CSL's $1.5B Illinois build to expand plasma drugs for rare diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQaEtkcTRKTWMydmtESGJaWWlvWUNaYk1wdDNvT25CWWY0cGtPUnhJdlU2U1kxekd0Nm4ySi1TdnBweFhZbHB3WTdKNUp6Z1pPdWJmZ1R6NlRjRDdNMFFvVlJndk5fVGtCakd0allaZ3ZoNEtmNUxFUGkyaFhQN01KQjhvOHlERDFGUTBVTFVYWVU0UnI0Z3VjZmMwVlV2UFB0SF9vQQ?oc=5","date":"2026-02-18","type":"pipeline","source":"MedCity News","summary":"Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug - MedCity News","headline":"Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQZEMzTEZiQWVXZmNYaVdvbXNjRnhVaVhTZ0tNT0FHU0VlRk41TWZEUjF1a2dCa0dxaU9LWTQ5NE9Deld4akpvUlV5TkZ6aEtKUFJyeVFlNE9vLWZSanppZlpXSTNTR3NmNE54U2l0NWxvNS1zMUhZZkJNb3hndTl2SVhvcEtsYktvSzR4ZlloNUM5U0VPb0xMczJ3OUlGOWFBcmtpOQ?oc=5","date":"2025-12-01","type":"pipeline","source":"TechStock²","summary":"CSL Limited (ASX:CSL) Share Price, Latest News and 2026 Outlook as of 1 December 2025 - TechStock²","headline":"CSL Limited (ASX:CSL) Share Price, Latest News and 2026 Outlook as of 1 December 2025 - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE0zYVhXS1loMVhUN3J3VEREMTFjSDAxa2tXVVFwdFN4OVVVUEpYM1RlMi1aU1lKOTBGTXZhRDYtZC1taFZPOTc0Z2M5QWFQaGh5WEd6cmE2ZVlHR1V0RmItNVdEMFJfcXNJTFJmNTAta25GMnZYUDBOUGhB?oc=5","date":"2025-11-18","type":"pipeline","source":"Seeking Alpha","summary":"CSL announces $1.5B investment in the U.S. (CSLLY:OTCMKTS) - Seeking Alpha","headline":"CSL announces $1.5B investment in the U.S. (CSLLY:OTCMKTS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQbURmTE1uekN3eDAwaldSNHZJUU9wdzh2OEp1M0JHRmdreTFUSGpTWFB6YThKcWpNYWpsMmRQMU92ZDBDcTd2ZWhRRExMdzhNdjZ1c3FvOXhBWEMwdjUyeXgxamJRZ2hwWEs5cWxaNUJPOElNaW9wejNYeE9kNWxDVXk4U1hsWDFyZ0ZCamlTWV9NQjlhZlpPY2tPWnRlaVNxWWhYQlNRRUlPLUVWRTFxQmxMOVNhNVRQUjZF?oc=5","date":"2025-10-26","type":"pipeline","source":"Stock Titan","summary":"CSL (CSLLY) wins ISPE 2025 Facility of the Year; Broadmeadows handles 10M litres - Stock Titan","headline":"CSL (CSLLY) wins ISPE 2025 Facility of the Year; Broadmeadows handles 10M litres","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTFBmN2FONzVxbFNYeDBUOHhFZTRYbzhsaXRFZmhFSGlyb0M4UmQteWduWG5rYUctTUpKcGlhdHdCTElST2w0aTlRcjMzYVZaSHdXbUZzeg?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"CSLLY Stock Price, News & Analysis - Stock Titan","headline":"CSLLY Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQWVBTeGlZUTJhcE8wQzcxMnVhbUQtbWxJNFVyd2NKYXF2NGNiODF3NFdoT19TZ1J2TGVJaGZiZTJOc3VxS08zVXpGYzhxeHN3SWlXeWJyaklsbnEybE43YnV6T3R6a0JSc0o3VDVxcmNoNDR6Ym92Q1RUT0o4VzkzVlZGTQ?oc=5","date":"2022-12-03","type":"pipeline","source":"MarketBeat","summary":"Why CSL Ltd Stock Could Be Worth a Look - MarketBeat","headline":"Why CSL Ltd Stock Could Be Worth a Look","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNcjNwUW1JY29qS0Z2ZXJWUEd4RDI4YWlPUlIwUERXNjBqN0pNM3BGYThTemJWUW5FYnZNclB5eTFIalpsdUVlaG5FbFdsMHRRenEtU3NfTUliQ3pFLVVLV3hZTFNCYnl1ZE1BOG9CSXUwN1Y1OWFOc21lTkJ5ZXBHSnVOSVpRWW5oMzl4T1p3WTNRa3ZPSFQwdlB1dS12QQ?oc=5","date":"2022-08-02","type":"pipeline","source":"Business Wire","summary":"Finalization of Vifor Pharma acquisition - Business Wire","headline":"Finalization of Vifor Pharma acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxON1NUYUdYcUtqM1pfei1iNVJuSURBcFg1d1ZRYzVySU9QamVSRzJ2ZUdVNVpkTFRUQUVjU0g5SE52cGUweHBDYndUTlRGUk56NVdtZjRSa0daclQ3Mnl4N2J2ejAtRUNmbVBkZTlOaEZKakJDZUJ0WXBCdmU1NTRpWjZVZVhId0o5LWZaTWE3M2MyblluQlgzTGo1ZnNGOUZpaFJVQUgyeVJMVXJHUE9uMmZSTVJNdnJSMkZLWjlKaDFiZEJYOHRTNEladVhHanB4YUhPbnVraUhhN2dJZmsxSUtjU2RxTlNJbTdMQW0tT1hadFVyY2o0WG5oY2taX0p4?oc=5","date":"2022-01-18","type":"pipeline","source":"Business Wire","summary":"CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd. - Business Wire","headline":"CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowJBVV95cUxQSS05TW5Fb01Na3BDb05YV1VIU2J5TVdSMHBVNE90eUM1YWhPdFhQNm1PdFoyamRkZk1KMGpidG1yLTk0Rkg0S1dyVU5BdFVla3ZRaEp2Smx4MUpZNXlTSXd1Y3BpaE9XWHgwZ05WSl8xZ0RvcU55MG5Hd0xIX01Ha24taUVURDlvaC03X0pVN0J6OUNqemJOUG1mZGVISktOUU81ZWJzU2tEREh0bUUwUGQ3elpyZlFESkRNdmpEeUF2QUVNcU5xM2JJWkwwTE5OMlQtY0dsSElva2NwX1p6eTREdWtBWFN5YjlKSzhKRmVtem9GS2hBNlN1Smxsa3U2Z3ExaDJFMl9XX3ZfaUNCbm0xVzYwclJnQTJKaVB3RFdUMVE?oc=5","date":"2020-05-27","type":"deal","source":"Thermo Fisher Scientific","summary":"Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services - Thermo Fisher Scientific","headline":"Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBRTWhhTWRyek5lWWVOUFh4Z0lSMTZveUhzeEpUMzVJZFpWcnJyZ0g5aWYwbjFRZlFvQVRucTJNTVpKVzQ4UFJ3NlVzaHljX2tXY2U0?oc=5","date":"2017-07-25","type":"pipeline","source":"Yahoo Finance Australia","summary":"CSL Limited (CSLLY) stock price, news, quote and history - Yahoo Finance Australia","headline":"CSL Limited (CSLLY) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"Hizentra","drugSlug":"immunoglobulin","patentNumber":"","type":"Patent Cliff","expiryDate":"2029-06-01","territory":"US","annualRevenue":1200000000},{"drugName":"Privigen","drugSlug":"immunoglobulin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":800000000}],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Baxter International","Grifols","Bioverativ"],"therapeuticFocus":["Immunology","Hematology"],"financials":{"source":"sec_edgar+yahoo","revenue":15430000000,"revenuePeriod":"2025-06-30","revenueHistory":[{"period":"2025-06-30","value":15430000000},{"period":"2024-06-30","value":14690000000},{"period":"2023-06-30","value":13174000000},{"period":"2022-06-30","value":10493100000}],"grossProfit":7951000000,"grossProfitHistory":[{"period":"2025-06-30","value":7951000000},{"period":"2024-06-30","value":7561000000},{"period":"2023-06-30","value":6708000000},{"period":"2022-06-30","value":5663500000}],"rdSpend":1359000000,"rdSpendHistory":[{"period":"2025-06-30","value":1359000000},{"period":"2024-06-30","value":1430000000},{"period":"2023-06-30","value":1235000000},{"period":"2022-06-30","value":1156200000}],"sgaSpend":2616000000,"operatingIncome":2959000000,"operatingIncomeHistory":[{"period":"2025-06-30","value":2959000000},{"period":"2024-06-30","value":2764000000},{"period":"2023-06-30","value":2102000000},{"period":"2022-06-30","value":2316100000}],"netIncome":3002000000,"netIncomeHistory":[{"period":"2025-06-30","value":3002000000},{"period":"2024-06-30","value":2642000000},{"period":"2023-06-30","value":2194000000},{"period":"2022-06-30","value":2254700000}],"eps":1.5425,"epsHistory":[{"period":"2025-06-30","value":1.5425},{"period":"2024-06-30","value":1.3625},{"period":"2023-06-30","value":1.1325},{"period":"2022-06-30","value":1.2}],"cash":2157000000,"cashHistory":[{"period":"2025-06-30","value":2157000000},{"period":"2024-06-30","value":1657000000},{"period":"2023-06-30","value":1548000000},{"period":"2022-06-30","value":10436400000}],"totalAssets":39403999999.9997,"totalLiabilities":17996999999.9999,"totalDebt":11498000000,"equity":19335000000.0001,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":-1017000000,"capexHistory":[{"period":"2025-06-30","value":-1017000000},{"period":"2024-06-30","value":-1258000000},{"period":"2023-06-30","value":-1692000000},{"period":"2022-06-30","value":-1247700000}],"freeCashflow":2544000000,"dividendsPaid":-1434000000,"buybacks":null,"employees":29904,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":1180000000,"ebit":2753000000,"ebitda":3229000000,"period":"2024-12-31","revenue":8213000000,"epsBasic":1.0375,"netIncome":2007000000,"rdExpense":646000000,"epsDiluted":1.0325,"grossProfit":4279000000,"operatingIncome":1977000000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":17.58,"previousClose":17.8,"fiftyTwoWeekHigh":44.85,"fiftyTwoWeekLow":17.53,"fiftyTwoWeekRange":"17.53 - 44.855","fiftyDayAverage":23.76,"twoHundredDayAverage":30.17,"beta":0.14,"enterpriseValue":20372107264,"forwardPE":10.3,"priceToBook":1.82,"priceToSales":2.19,"enterpriseToRevenue":1.32,"enterpriseToEbitda":4.21,"pegRatio":0,"ebitda":4840000000,"ebitdaMargin":31.4,"freeCashflow":1848125056,"operatingCashflow":3604000000,"totalDebt":11137999872,"debtToEquity":54.4,"currentRatio":2.57,"returnOnAssets":6.6,"returnOnEquity":6.7,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":1,"targetMeanPrice":27.96,"targetHighPrice":27.96,"targetLowPrice":27.96,"dividendRate":0.72,"payoutRatio":0.45,"fiveYearAvgDividendYield":1.45,"exDividendDate":1773187200,"insiderHeldPercent":0,"institutionHeldPercent":0,"sharesOutstanding":1915647916,"floatShares":481822248,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.54,"epsForward":1.7,"revenuePerShare":7.96,"bookValue":9.67,"officers":[{"age":54,"name":"Mr. Andy  Schmeltz","title":"Chief Commercial Officer"},{"age":62,"name":"Mr. Gordon  Naylor BEng (Hons), C.P.A., DipCompSc, M.B.A.","title":"CEO, MD & Director"},{"age":51,"name":"Mr. Ken  Lim","title":"Chief Financial Officer"},{"age":62,"name":"Dr. Mary  Oates Ph.D.","title":"Executive VP & COO"},{"age":null,"name":"Mr. Mark  Dehring","title":"Head of Investor Relations"},{"age":64,"name":"Mr. Gregory  Boss B.S., BS(Hons), J.D.","title":"Executive VP of Legal & Group General Counsel"},{"age":null,"name":"Ms. Amy Van Buren","title":"Chief People Officer"},{"age":66,"name":"Dr. William  Mezzanotte M.D., M.P.H.","title":"Chief Medical Officer, Executive VP and Head of Research & Development"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.csl.com","phone":"61 3 9389 1911"}}